TOPICAL MEK INHIBITOR PROGRAMS
| Program | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|
| Neurofibromatosis Type 1 Treatment of Cutaneous Neurofibromas | ||||
| Squamous Cell Carcinoma Prevention in High-Risk Transplant Recipients | ||||
| Congenital Birthmarks Non-surgical Treatment | ||||
| Program | Stage | |
|---|---|---|
| Neurofibromatosis Type 1tar | Treatment of Cutaneous Neurofibromas | Phase 2 |
| Squamous Cell Carcinoma | Prevention in High-Risk Transplant Recipients | Preclinical |
| Congenital Birthmarks | Non-surgical Treatment | Preclinical |